Protagonist Therapeutics, Inc. (NASDAQ:PTGX) has a beta value of 1.55 and has seen 457,738 shares traded in the last trading session. The company, currently valued at $831.32 Million, closed the last trade at $21.73 per share which meant it gained $0.23 on the day or 1.07% during that session. The PTGX stock price is -10.54% off its 52-week high price of $24.02 and 79.43% above the 52-week low of $4.47. If we look at the company’s 10-day average daily trading volume, we find that it stood at 445.32 Million shares traded. The 3-month trading volume is 358.58 Million shares.
The consensus among analysts is that Protagonist Therapeutics, Inc. (PTGX) is a Buy stock at the moment, with a recommendation rating of 1.5. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 4 have rated it as a Hold, with 4 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.47.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) trade information
Sporting 1.07% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Thursday, Nov 19 when the PTGX stock price touched $23.75- or saw a rise of 8.51%. Year-to-date, Protagonist Therapeutics, Inc. shares have moved 208.23%, while the 5-day performance has seen it change -2.16%. Over the past 30 days, the shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) have changed 7.95%. Short interest in the company has seen 2.55 Million shares shorted with days to cover at 0.01.
Wall Street analysts have a consensus price target for the stock at $31.75, which means that the shares’ value could jump 46.11% from current levels. The projected low price target is $27 while the price target rests at a high of $37. In that case, then, we find that the current price level is +70.27% off the targeted high while a plunge would see the stock lose 24.25% from current levels.
Protagonist Therapeutics, Inc. (PTGX) estimates and forecasts
Figures show that Protagonist Therapeutics, Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained +36.71% over the past 6 months, with this year growth rate of -35.23%, compared to 14.5% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 25.4% and 25% for the next quarter. Revenue growth from the last financial year stood is estimated to be +11475.8%.
4 analysts offering their estimates for the company have set an average revenue estimate of $4.4 Million for the current quarter. 2 have an estimated revenue figure of $2.5 Million for the next quarter concluding in March 01, 2021. Year-ago sales stood $2.72 Million and $3.65 Million respectively for this quarter and the next, and analysts expect sales will grow by 61.8% for the current quarter and -31.5% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -31.3% over the past 5 years. Earnings growth for 2020 is a modest -71.3%.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX)’s Major holders
Insiders own 1.38% of the company shares, while shares held by institutions stand at 102.89% with a share float percentage of 104.33%. Investors are also buoyed by the number of investors in a company, with Protagonist Therapeutics, Inc. having a total of 147 institutions that hold shares in the company. The top two institutional holders are FMR, LLC with over 5.2 Million shares worth more than $101.68 Million. As of September 29, 2020, FMR, LLC held 13.6% of shares outstanding.
The other major institutional holder is RTW Investments LP, with the holding of over 3.41 Million shares as of September 29, 2020. The firm’s total holdings are worth over $66.65 Million and represent 8.91% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Series Small Cap Opportunities Fund and Fidelity Growth Company Fund. As of July 30, 2020, the former fund manager holds about 3.63% shares in the company for having 1388429 shares of worth $21.84 Million while later fund manager owns 954.54 Thousand shares of worth $21.38 Million as of August 30, 2020, which makes it owner of about 2.5% of company’s outstanding stock.